Lilly Just Huge Vote: Morgan Stanley Bets on Mounjaro
A major investment bank just signaled a powerful vote of confidence in Lilly's GLP-1 strategy. This article breaks do...
Understand what to expect from financial planning and accounting services. Make informed decisions for your financial future.
23,685 articlesA major investment bank just signaled a powerful vote of confidence in Lilly's GLP-1 strategy. This article breaks do...
Memory-chip giants Micron and SK Hynix push into the $1 trillion market-cap club, signaling renewed confidence in AI-...
Pfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
Alaska Air Group stock surged this week as investors weighed fuel-cost pressures against resilient demand and discipl...
A top AI analyst argues the AI revolution is still in its early stages, with ASML’s hefty backlog and robust Q1 2026 ...
Two pharma giants are wighting for a leadership position in immunology. This piece explains why Johnson Johnson hopes...
Remax Premier Realty credits a laser-focused agent-recruitment program for surging growth from 2021-2025, culminating...
Defense technology is approaching a market shakeout as government procurement reforms accelerate purchases and ventur...
Eli Lilly’s GLP-1 drugs are redefining growth in obesity and diabetes treatment. This article lays out why the stock ...
Wegovy continues to lead the U.S. GLP-1 market despite Eli Lilly's Foundayo launch. Investors are weighing uptake, pa...
Schg’s 32× start melt-up is shaping a pivotal market moment: can a growth-heavy ETF sustain gains on high valuations,...
Broadcom delivered solid quarterly results, but AI guidance disappointed some investors, sending shares lower. Analys...